<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01572818</url>
  </required_header>
  <id_info>
    <org_study_id>2008-A00636-49</org_study_id>
    <secondary_id>PHRC/07-05</secondary_id>
    <secondary_id>CIC0203/070</secondary_id>
    <nct_id>NCT01572818</nct_id>
  </id_info>
  <brief_title>Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients</brief_title>
  <acronym>SAINPOS</acronym>
  <official_title>Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy of phlebotomy on insulin sensitivity as
      evaluated by euglycemic-hyperinsulinic clamp in insulin resistance-associated hepatic iron
      overload patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to evaluate in patients with HSD effects of treatment
      with phlebotomy rules with lifestyle and dietary rules versus lifestyle modifications alone
      on peripheral insulin resistance (assessed by hyperinsulinemic clamp).

      Secondary objectives are:

        -  to study in all patients with HSD the relationship between the amount of iron
           intrahepatic and degree of peripheral insulin resistance and liver before therapeutic
           intervention.

        -  to study and compare the effects of phlebotomy treatment versus no treatment on:

             -  Plasma levels of adipocytokines,

             -  Plasma concentrations of inflammatory markers and markers of insulin resistance,

             -  The serum ferritin,

             -  The post-hepatic clearance of insulin,

             -  The surface of the abdominal visceral fat and subcutaneous abdominal.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose Infusion Rate by euglycemic-hyperinsulinic clamp</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hepatic parameters</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammation markers</measure>
    <time_frame>6 months</time_frame>
    <description>IL-6, TNF alpha, CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipokins markers</measure>
    <time_frame>6 months</time_frame>
    <description>adiponectin, PAI1, leptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SHBG</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic iron overload (MRI)</measure>
    <time_frame>6 months</time_frame>
    <description>transaminase (ALT, AST), gamma GT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal and sub-cutaneous fat surface (MRI)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iron parameters</measure>
    <time_frame>at 6 months</time_frame>
    <description>serum iron, ferritin, saturation of transferrin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile</measure>
    <time_frame>at 6 months</time_frame>
    <description>HDL-c, LDL-c, triglycerides</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Iron Overload</condition>
  <arm_group>
    <arm_group_label>Phlebotomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>phlebotomy associated with dietary and lifestyle counseling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lifestyle counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dietary and lifestyle counseling</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>phlebotomy</intervention_name>
    <description>7 ml/kg without exceeding 500 mL</description>
    <arm_group_label>Phlebotomy</arm_group_label>
    <other_name>Non applicable.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>dietary and lifestyle counseling</intervention_name>
    <description>dietary and lifestyle counseling</description>
    <arm_group_label>Phlebotomy</arm_group_label>
    <arm_group_label>Lifestyle counseling</arm_group_label>
    <other_name>Non applicable.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 70 years

          -  Ferritin between 450 and 1000 µg/L

          -  Hepatic iron overload proved by MRI (CHF &gt;36 µmol/g)

          -  Body mass index &gt; 25 kg/m²

          -  Fasting glycemia &lt;1,26 g/L

          -  HbA1c &lt; 6,5%

          -  Signed written and informed consent

        Exclusion Criteria:

          -  Other causes of hyperferritinemia:

               -  Inflammatory syndrome (CRP &gt;10 mg/L) or inflammatory, immune or malignant
                  diseases

               -  Hyperferritinemia-cataract syndrome (familial cataract or personal history of
                  cataract before 50 years old)

               -  Low ceruloplasmin level

               -  Porphyria (cutaneous signs)

               -  Haemochromatosis established by the genotype (C282Y homozygous or C282Y/H63D
                  coumpound heterozygous genotypes)

          -  Contraindication of phlebotomy

               -  Haemoglobin &lt;13,5 g/dL (threshold established by the Etablissement Français du
                  Sang)

               -  Heart failure or coronary heart diseases

               -  Hepatic failure, renal (GFR &lt;50mL/min) or respiratory insufficiency (chronic
                  dyspnea)

               -  Poor venous system

          -  Viral, immune, genetic, vascular, malignant or toxic chronic hepatic disease

          -  Alcohol consumption more than 21 doses per week during 5 years or more

          -  Type 1 or type 2 diabetes

          -  Oral anti-diabetic, corticoids or immune suppressor drugs

          -  Hepatic severe disease

          -  Claustrophobia, having a pace-maker or intracerebral clips

          -  Subjects deprived of their liberty by judicial or administrative decision, subjects
             that are not affiliated to social security or topics exclusion period of a previous
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice BONNET, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Bellissant, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>RennesUniversity Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Nantes</city>
        <zip>F-44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rennes</city>
        <zip>F-35203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2011</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phlebotomy</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Iron Overload</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

